Front Pharmacol:黄芩苷可通过抑制TLR4的表达和NF-kB活化对抗LPS诱导的肝脏炎症

2017-10-03 MedSci MedSci原创

作为一种有力的刺激,脂多糖(LPS)具有通过激活体内受体(TLR)4引起细胞损伤的能力,然后核因子κB(NF-κB)转位到细胞核中并改变相关炎症的表达基因。黄芩苷是从黄芩中提取的化合物,具有抗炎、抗氧化及抗菌等特点。然而,关于黄芩苷对LPS诱导的肝脏炎症的影响目前尚未完全阐明。本研究旨在研究黄芩苷对鸡LPS诱导的肝脏炎症的抗炎作用及其潜在的分子机制。组织病理学变化、血清生化分析以及NO水平和髓过氧

作为一种有力的刺激,脂多糖(LPS)具有通过激活体内受体(TLR)4引起细胞损伤的能力,然后核因子κB(NF-κB)转位到细胞核中并改变相关炎症的表达基因。黄芩苷是从黄芩中提取的化合物,具有抗炎、抗氧化及抗菌等特点。然而,关于黄芩苷对LPS诱导的肝脏炎症的影响目前尚未完全阐明。

本研究旨在研究黄芩苷对鸡LPS诱导的肝脏炎症的抗炎作用及其潜在的分子机制。组织病理学变化、血清生化分析以及NO水平和髓过氧化物酶活性的结果显示,黄芩苷预处理可改善LPS诱导的肝脏炎症。ELISA和qPCR检测分析显示,黄芩苷呈剂量依赖性的抑制IL-1β、IL-6和TNF-α的产生。

此外,黄芩苷可显著降低诱导型一氧化氮合酶(iNOS)和环氧合酶-2(COX-2)的mRNA表达。TLR4是LPS感染的重要传感器。分子研究表明,黄芩苷预处理抑制了TLR4的表达。此外,黄芩苷预处理可抑制NF-kB信号通路的激活。

总之,该研究结果表明,黄芩苷抗炎机制是通过抑制TLR4的表达和NF-kB活化,黄芩苷预处理可对抗鸡LPS诱导的肝脏炎症。

原始出处:

Ping Cheng, Tong Wang, et al., Baicalin Alleviates Lipopolysaccharide-Induced Liver Inflammation in Chicken by Suppressing TLR4-Mediated NF-κB Pathway. Front Pharmacol. 2017; 8: 547. Published online 2017 Aug 18. doi: 10.3389/fphar.2017.00547

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (13)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1746606, encodeId=c6ff1e4660649, content=<a href='/topic/show?id=989d1e525e5' target=_blank style='color:#2F92EE;'>#TLR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17525, encryptionId=989d1e525e5, topicName=TLR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd2d35803070, createdName=lilianxiang, createdTime=Fri Apr 06 13:22:00 CST 2018, time=2018-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787337, encodeId=4d251e873370c, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Feb 28 23:22:00 CST 2018, time=2018-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996054, encodeId=5d871996054d7, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Wed Nov 15 05:22:00 CST 2017, time=2017-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788252, encodeId=b9d41e882524d, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sat May 26 04:22:00 CST 2018, time=2018-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908321, encodeId=40511908321e9, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Mon Jan 22 03:22:00 CST 2018, time=2018-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=251449, encodeId=1941251449f0, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3da1990174, createdName=yfjms, createdTime=Mon Oct 09 06:57:45 CST 2017, time=2017-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1390025, encodeId=da781390025f6, content=<a href='/topic/show?id=2de31e53537' target=_blank style='color:#2F92EE;'>#TLR4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17535, encryptionId=2de31e53537, topicName=TLR4)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/F39C49DDAFA7119F6BF29B57B788FE2C/100, createdBy=0ca42500047, createdName=ms3875500703114551, createdTime=Thu Oct 05 12:22:00 CST 2017, time=2017-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1448759, encodeId=2b1b1448e5902, content=<a href='/topic/show?id=4a6f1104071' target=_blank style='color:#2F92EE;'>#LPS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11040, encryptionId=4a6f1104071, topicName=LPS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88135422756, createdName=shijzhiewnjhch, createdTime=Thu Oct 05 12:22:00 CST 2017, time=2017-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1529600, encodeId=cf1d152960056, content=<a href='/topic/show?id=e1c0814517e' target=_blank style='color:#2F92EE;'>#肝脏炎症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81451, encryptionId=e1c0814517e, topicName=肝脏炎症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=be0e11959960, createdName=zsyan, createdTime=Thu Oct 05 12:22:00 CST 2017, time=2017-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1536959, encodeId=fc1e15369590b, content=<a href='/topic/show?id=f1c512e304f' target=_blank style='color:#2F92EE;'>#NF-kB#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12730, encryptionId=f1c512e304f, topicName=NF-kB)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2ca12754731, createdName=jichang, createdTime=Thu Oct 05 12:22:00 CST 2017, time=2017-10-05, status=1, ipAttribution=)]
    2018-04-06 lilianxiang
  2. [GetPortalCommentsPageByObjectIdResponse(id=1746606, encodeId=c6ff1e4660649, content=<a href='/topic/show?id=989d1e525e5' target=_blank style='color:#2F92EE;'>#TLR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17525, encryptionId=989d1e525e5, topicName=TLR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd2d35803070, createdName=lilianxiang, createdTime=Fri Apr 06 13:22:00 CST 2018, time=2018-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787337, encodeId=4d251e873370c, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Feb 28 23:22:00 CST 2018, time=2018-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996054, encodeId=5d871996054d7, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Wed Nov 15 05:22:00 CST 2017, time=2017-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788252, encodeId=b9d41e882524d, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sat May 26 04:22:00 CST 2018, time=2018-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908321, encodeId=40511908321e9, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Mon Jan 22 03:22:00 CST 2018, time=2018-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=251449, encodeId=1941251449f0, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3da1990174, createdName=yfjms, createdTime=Mon Oct 09 06:57:45 CST 2017, time=2017-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1390025, encodeId=da781390025f6, content=<a href='/topic/show?id=2de31e53537' target=_blank style='color:#2F92EE;'>#TLR4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17535, encryptionId=2de31e53537, topicName=TLR4)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/F39C49DDAFA7119F6BF29B57B788FE2C/100, createdBy=0ca42500047, createdName=ms3875500703114551, createdTime=Thu Oct 05 12:22:00 CST 2017, time=2017-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1448759, encodeId=2b1b1448e5902, content=<a href='/topic/show?id=4a6f1104071' target=_blank style='color:#2F92EE;'>#LPS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11040, encryptionId=4a6f1104071, topicName=LPS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88135422756, createdName=shijzhiewnjhch, createdTime=Thu Oct 05 12:22:00 CST 2017, time=2017-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1529600, encodeId=cf1d152960056, content=<a href='/topic/show?id=e1c0814517e' target=_blank style='color:#2F92EE;'>#肝脏炎症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81451, encryptionId=e1c0814517e, topicName=肝脏炎症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=be0e11959960, createdName=zsyan, createdTime=Thu Oct 05 12:22:00 CST 2017, time=2017-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1536959, encodeId=fc1e15369590b, content=<a href='/topic/show?id=f1c512e304f' target=_blank style='color:#2F92EE;'>#NF-kB#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12730, encryptionId=f1c512e304f, topicName=NF-kB)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2ca12754731, createdName=jichang, createdTime=Thu Oct 05 12:22:00 CST 2017, time=2017-10-05, status=1, ipAttribution=)]
    2018-02-28 jj000001
  3. [GetPortalCommentsPageByObjectIdResponse(id=1746606, encodeId=c6ff1e4660649, content=<a href='/topic/show?id=989d1e525e5' target=_blank style='color:#2F92EE;'>#TLR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17525, encryptionId=989d1e525e5, topicName=TLR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd2d35803070, createdName=lilianxiang, createdTime=Fri Apr 06 13:22:00 CST 2018, time=2018-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787337, encodeId=4d251e873370c, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Feb 28 23:22:00 CST 2018, time=2018-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996054, encodeId=5d871996054d7, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Wed Nov 15 05:22:00 CST 2017, time=2017-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788252, encodeId=b9d41e882524d, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sat May 26 04:22:00 CST 2018, time=2018-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908321, encodeId=40511908321e9, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Mon Jan 22 03:22:00 CST 2018, time=2018-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=251449, encodeId=1941251449f0, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3da1990174, createdName=yfjms, createdTime=Mon Oct 09 06:57:45 CST 2017, time=2017-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1390025, encodeId=da781390025f6, content=<a href='/topic/show?id=2de31e53537' target=_blank style='color:#2F92EE;'>#TLR4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17535, encryptionId=2de31e53537, topicName=TLR4)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/F39C49DDAFA7119F6BF29B57B788FE2C/100, createdBy=0ca42500047, createdName=ms3875500703114551, createdTime=Thu Oct 05 12:22:00 CST 2017, time=2017-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1448759, encodeId=2b1b1448e5902, content=<a href='/topic/show?id=4a6f1104071' target=_blank style='color:#2F92EE;'>#LPS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11040, encryptionId=4a6f1104071, topicName=LPS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88135422756, createdName=shijzhiewnjhch, createdTime=Thu Oct 05 12:22:00 CST 2017, time=2017-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1529600, encodeId=cf1d152960056, content=<a href='/topic/show?id=e1c0814517e' target=_blank style='color:#2F92EE;'>#肝脏炎症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81451, encryptionId=e1c0814517e, topicName=肝脏炎症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=be0e11959960, createdName=zsyan, createdTime=Thu Oct 05 12:22:00 CST 2017, time=2017-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1536959, encodeId=fc1e15369590b, content=<a href='/topic/show?id=f1c512e304f' target=_blank style='color:#2F92EE;'>#NF-kB#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12730, encryptionId=f1c512e304f, topicName=NF-kB)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2ca12754731, createdName=jichang, createdTime=Thu Oct 05 12:22:00 CST 2017, time=2017-10-05, status=1, ipAttribution=)]
    2017-11-15 yb6560
  4. [GetPortalCommentsPageByObjectIdResponse(id=1746606, encodeId=c6ff1e4660649, content=<a href='/topic/show?id=989d1e525e5' target=_blank style='color:#2F92EE;'>#TLR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17525, encryptionId=989d1e525e5, topicName=TLR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd2d35803070, createdName=lilianxiang, createdTime=Fri Apr 06 13:22:00 CST 2018, time=2018-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787337, encodeId=4d251e873370c, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Feb 28 23:22:00 CST 2018, time=2018-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996054, encodeId=5d871996054d7, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Wed Nov 15 05:22:00 CST 2017, time=2017-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788252, encodeId=b9d41e882524d, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sat May 26 04:22:00 CST 2018, time=2018-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908321, encodeId=40511908321e9, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Mon Jan 22 03:22:00 CST 2018, time=2018-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=251449, encodeId=1941251449f0, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3da1990174, createdName=yfjms, createdTime=Mon Oct 09 06:57:45 CST 2017, time=2017-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1390025, encodeId=da781390025f6, content=<a href='/topic/show?id=2de31e53537' target=_blank style='color:#2F92EE;'>#TLR4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17535, encryptionId=2de31e53537, topicName=TLR4)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/F39C49DDAFA7119F6BF29B57B788FE2C/100, createdBy=0ca42500047, createdName=ms3875500703114551, createdTime=Thu Oct 05 12:22:00 CST 2017, time=2017-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1448759, encodeId=2b1b1448e5902, content=<a href='/topic/show?id=4a6f1104071' target=_blank style='color:#2F92EE;'>#LPS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11040, encryptionId=4a6f1104071, topicName=LPS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88135422756, createdName=shijzhiewnjhch, createdTime=Thu Oct 05 12:22:00 CST 2017, time=2017-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1529600, encodeId=cf1d152960056, content=<a href='/topic/show?id=e1c0814517e' target=_blank style='color:#2F92EE;'>#肝脏炎症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81451, encryptionId=e1c0814517e, topicName=肝脏炎症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=be0e11959960, createdName=zsyan, createdTime=Thu Oct 05 12:22:00 CST 2017, time=2017-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1536959, encodeId=fc1e15369590b, content=<a href='/topic/show?id=f1c512e304f' target=_blank style='color:#2F92EE;'>#NF-kB#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12730, encryptionId=f1c512e304f, topicName=NF-kB)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2ca12754731, createdName=jichang, createdTime=Thu Oct 05 12:22:00 CST 2017, time=2017-10-05, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1746606, encodeId=c6ff1e4660649, content=<a href='/topic/show?id=989d1e525e5' target=_blank style='color:#2F92EE;'>#TLR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17525, encryptionId=989d1e525e5, topicName=TLR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd2d35803070, createdName=lilianxiang, createdTime=Fri Apr 06 13:22:00 CST 2018, time=2018-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787337, encodeId=4d251e873370c, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Feb 28 23:22:00 CST 2018, time=2018-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996054, encodeId=5d871996054d7, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Wed Nov 15 05:22:00 CST 2017, time=2017-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788252, encodeId=b9d41e882524d, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sat May 26 04:22:00 CST 2018, time=2018-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908321, encodeId=40511908321e9, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Mon Jan 22 03:22:00 CST 2018, time=2018-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=251449, encodeId=1941251449f0, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3da1990174, createdName=yfjms, createdTime=Mon Oct 09 06:57:45 CST 2017, time=2017-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1390025, encodeId=da781390025f6, content=<a href='/topic/show?id=2de31e53537' target=_blank style='color:#2F92EE;'>#TLR4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17535, encryptionId=2de31e53537, topicName=TLR4)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/F39C49DDAFA7119F6BF29B57B788FE2C/100, createdBy=0ca42500047, createdName=ms3875500703114551, createdTime=Thu Oct 05 12:22:00 CST 2017, time=2017-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1448759, encodeId=2b1b1448e5902, content=<a href='/topic/show?id=4a6f1104071' target=_blank style='color:#2F92EE;'>#LPS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11040, encryptionId=4a6f1104071, topicName=LPS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88135422756, createdName=shijzhiewnjhch, createdTime=Thu Oct 05 12:22:00 CST 2017, time=2017-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1529600, encodeId=cf1d152960056, content=<a href='/topic/show?id=e1c0814517e' target=_blank style='color:#2F92EE;'>#肝脏炎症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81451, encryptionId=e1c0814517e, topicName=肝脏炎症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=be0e11959960, createdName=zsyan, createdTime=Thu Oct 05 12:22:00 CST 2017, time=2017-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1536959, encodeId=fc1e15369590b, content=<a href='/topic/show?id=f1c512e304f' target=_blank style='color:#2F92EE;'>#NF-kB#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12730, encryptionId=f1c512e304f, topicName=NF-kB)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2ca12754731, createdName=jichang, createdTime=Thu Oct 05 12:22:00 CST 2017, time=2017-10-05, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1746606, encodeId=c6ff1e4660649, content=<a href='/topic/show?id=989d1e525e5' target=_blank style='color:#2F92EE;'>#TLR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17525, encryptionId=989d1e525e5, topicName=TLR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd2d35803070, createdName=lilianxiang, createdTime=Fri Apr 06 13:22:00 CST 2018, time=2018-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787337, encodeId=4d251e873370c, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Feb 28 23:22:00 CST 2018, time=2018-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996054, encodeId=5d871996054d7, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Wed Nov 15 05:22:00 CST 2017, time=2017-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788252, encodeId=b9d41e882524d, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sat May 26 04:22:00 CST 2018, time=2018-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908321, encodeId=40511908321e9, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Mon Jan 22 03:22:00 CST 2018, time=2018-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=251449, encodeId=1941251449f0, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3da1990174, createdName=yfjms, createdTime=Mon Oct 09 06:57:45 CST 2017, time=2017-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1390025, encodeId=da781390025f6, content=<a href='/topic/show?id=2de31e53537' target=_blank style='color:#2F92EE;'>#TLR4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17535, encryptionId=2de31e53537, topicName=TLR4)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/F39C49DDAFA7119F6BF29B57B788FE2C/100, createdBy=0ca42500047, createdName=ms3875500703114551, createdTime=Thu Oct 05 12:22:00 CST 2017, time=2017-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1448759, encodeId=2b1b1448e5902, content=<a href='/topic/show?id=4a6f1104071' target=_blank style='color:#2F92EE;'>#LPS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11040, encryptionId=4a6f1104071, topicName=LPS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88135422756, createdName=shijzhiewnjhch, createdTime=Thu Oct 05 12:22:00 CST 2017, time=2017-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1529600, encodeId=cf1d152960056, content=<a href='/topic/show?id=e1c0814517e' target=_blank style='color:#2F92EE;'>#肝脏炎症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81451, encryptionId=e1c0814517e, topicName=肝脏炎症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=be0e11959960, createdName=zsyan, createdTime=Thu Oct 05 12:22:00 CST 2017, time=2017-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1536959, encodeId=fc1e15369590b, content=<a href='/topic/show?id=f1c512e304f' target=_blank style='color:#2F92EE;'>#NF-kB#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12730, encryptionId=f1c512e304f, topicName=NF-kB)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2ca12754731, createdName=jichang, createdTime=Thu Oct 05 12:22:00 CST 2017, time=2017-10-05, status=1, ipAttribution=)]
    2017-10-09 yfjms

    学习了

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1746606, encodeId=c6ff1e4660649, content=<a href='/topic/show?id=989d1e525e5' target=_blank style='color:#2F92EE;'>#TLR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17525, encryptionId=989d1e525e5, topicName=TLR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd2d35803070, createdName=lilianxiang, createdTime=Fri Apr 06 13:22:00 CST 2018, time=2018-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787337, encodeId=4d251e873370c, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Feb 28 23:22:00 CST 2018, time=2018-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996054, encodeId=5d871996054d7, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Wed Nov 15 05:22:00 CST 2017, time=2017-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788252, encodeId=b9d41e882524d, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sat May 26 04:22:00 CST 2018, time=2018-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908321, encodeId=40511908321e9, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Mon Jan 22 03:22:00 CST 2018, time=2018-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=251449, encodeId=1941251449f0, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3da1990174, createdName=yfjms, createdTime=Mon Oct 09 06:57:45 CST 2017, time=2017-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1390025, encodeId=da781390025f6, content=<a href='/topic/show?id=2de31e53537' target=_blank style='color:#2F92EE;'>#TLR4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17535, encryptionId=2de31e53537, topicName=TLR4)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/F39C49DDAFA7119F6BF29B57B788FE2C/100, createdBy=0ca42500047, createdName=ms3875500703114551, createdTime=Thu Oct 05 12:22:00 CST 2017, time=2017-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1448759, encodeId=2b1b1448e5902, content=<a href='/topic/show?id=4a6f1104071' target=_blank style='color:#2F92EE;'>#LPS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11040, encryptionId=4a6f1104071, topicName=LPS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88135422756, createdName=shijzhiewnjhch, createdTime=Thu Oct 05 12:22:00 CST 2017, time=2017-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1529600, encodeId=cf1d152960056, content=<a href='/topic/show?id=e1c0814517e' target=_blank style='color:#2F92EE;'>#肝脏炎症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81451, encryptionId=e1c0814517e, topicName=肝脏炎症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=be0e11959960, createdName=zsyan, createdTime=Thu Oct 05 12:22:00 CST 2017, time=2017-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1536959, encodeId=fc1e15369590b, content=<a href='/topic/show?id=f1c512e304f' target=_blank style='color:#2F92EE;'>#NF-kB#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12730, encryptionId=f1c512e304f, topicName=NF-kB)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2ca12754731, createdName=jichang, createdTime=Thu Oct 05 12:22:00 CST 2017, time=2017-10-05, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1746606, encodeId=c6ff1e4660649, content=<a href='/topic/show?id=989d1e525e5' target=_blank style='color:#2F92EE;'>#TLR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17525, encryptionId=989d1e525e5, topicName=TLR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd2d35803070, createdName=lilianxiang, createdTime=Fri Apr 06 13:22:00 CST 2018, time=2018-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787337, encodeId=4d251e873370c, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Feb 28 23:22:00 CST 2018, time=2018-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996054, encodeId=5d871996054d7, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Wed Nov 15 05:22:00 CST 2017, time=2017-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788252, encodeId=b9d41e882524d, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sat May 26 04:22:00 CST 2018, time=2018-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908321, encodeId=40511908321e9, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Mon Jan 22 03:22:00 CST 2018, time=2018-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=251449, encodeId=1941251449f0, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3da1990174, createdName=yfjms, createdTime=Mon Oct 09 06:57:45 CST 2017, time=2017-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1390025, encodeId=da781390025f6, content=<a href='/topic/show?id=2de31e53537' target=_blank style='color:#2F92EE;'>#TLR4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17535, encryptionId=2de31e53537, topicName=TLR4)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/F39C49DDAFA7119F6BF29B57B788FE2C/100, createdBy=0ca42500047, createdName=ms3875500703114551, createdTime=Thu Oct 05 12:22:00 CST 2017, time=2017-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1448759, encodeId=2b1b1448e5902, content=<a href='/topic/show?id=4a6f1104071' target=_blank style='color:#2F92EE;'>#LPS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11040, encryptionId=4a6f1104071, topicName=LPS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88135422756, createdName=shijzhiewnjhch, createdTime=Thu Oct 05 12:22:00 CST 2017, time=2017-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1529600, encodeId=cf1d152960056, content=<a href='/topic/show?id=e1c0814517e' target=_blank style='color:#2F92EE;'>#肝脏炎症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81451, encryptionId=e1c0814517e, topicName=肝脏炎症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=be0e11959960, createdName=zsyan, createdTime=Thu Oct 05 12:22:00 CST 2017, time=2017-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1536959, encodeId=fc1e15369590b, content=<a href='/topic/show?id=f1c512e304f' target=_blank style='color:#2F92EE;'>#NF-kB#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12730, encryptionId=f1c512e304f, topicName=NF-kB)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2ca12754731, createdName=jichang, createdTime=Thu Oct 05 12:22:00 CST 2017, time=2017-10-05, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=1746606, encodeId=c6ff1e4660649, content=<a href='/topic/show?id=989d1e525e5' target=_blank style='color:#2F92EE;'>#TLR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17525, encryptionId=989d1e525e5, topicName=TLR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd2d35803070, createdName=lilianxiang, createdTime=Fri Apr 06 13:22:00 CST 2018, time=2018-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787337, encodeId=4d251e873370c, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Feb 28 23:22:00 CST 2018, time=2018-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996054, encodeId=5d871996054d7, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Wed Nov 15 05:22:00 CST 2017, time=2017-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788252, encodeId=b9d41e882524d, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sat May 26 04:22:00 CST 2018, time=2018-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908321, encodeId=40511908321e9, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Mon Jan 22 03:22:00 CST 2018, time=2018-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=251449, encodeId=1941251449f0, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3da1990174, createdName=yfjms, createdTime=Mon Oct 09 06:57:45 CST 2017, time=2017-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1390025, encodeId=da781390025f6, content=<a href='/topic/show?id=2de31e53537' target=_blank style='color:#2F92EE;'>#TLR4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17535, encryptionId=2de31e53537, topicName=TLR4)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/F39C49DDAFA7119F6BF29B57B788FE2C/100, createdBy=0ca42500047, createdName=ms3875500703114551, createdTime=Thu Oct 05 12:22:00 CST 2017, time=2017-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1448759, encodeId=2b1b1448e5902, content=<a href='/topic/show?id=4a6f1104071' target=_blank style='color:#2F92EE;'>#LPS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11040, encryptionId=4a6f1104071, topicName=LPS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88135422756, createdName=shijzhiewnjhch, createdTime=Thu Oct 05 12:22:00 CST 2017, time=2017-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1529600, encodeId=cf1d152960056, content=<a href='/topic/show?id=e1c0814517e' target=_blank style='color:#2F92EE;'>#肝脏炎症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81451, encryptionId=e1c0814517e, topicName=肝脏炎症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=be0e11959960, createdName=zsyan, createdTime=Thu Oct 05 12:22:00 CST 2017, time=2017-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1536959, encodeId=fc1e15369590b, content=<a href='/topic/show?id=f1c512e304f' target=_blank style='color:#2F92EE;'>#NF-kB#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12730, encryptionId=f1c512e304f, topicName=NF-kB)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2ca12754731, createdName=jichang, createdTime=Thu Oct 05 12:22:00 CST 2017, time=2017-10-05, status=1, ipAttribution=)]
  10. [GetPortalCommentsPageByObjectIdResponse(id=1746606, encodeId=c6ff1e4660649, content=<a href='/topic/show?id=989d1e525e5' target=_blank style='color:#2F92EE;'>#TLR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17525, encryptionId=989d1e525e5, topicName=TLR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd2d35803070, createdName=lilianxiang, createdTime=Fri Apr 06 13:22:00 CST 2018, time=2018-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787337, encodeId=4d251e873370c, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Feb 28 23:22:00 CST 2018, time=2018-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996054, encodeId=5d871996054d7, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Wed Nov 15 05:22:00 CST 2017, time=2017-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788252, encodeId=b9d41e882524d, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sat May 26 04:22:00 CST 2018, time=2018-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908321, encodeId=40511908321e9, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Mon Jan 22 03:22:00 CST 2018, time=2018-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=251449, encodeId=1941251449f0, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3da1990174, createdName=yfjms, createdTime=Mon Oct 09 06:57:45 CST 2017, time=2017-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1390025, encodeId=da781390025f6, content=<a href='/topic/show?id=2de31e53537' target=_blank style='color:#2F92EE;'>#TLR4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17535, encryptionId=2de31e53537, topicName=TLR4)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/F39C49DDAFA7119F6BF29B57B788FE2C/100, createdBy=0ca42500047, createdName=ms3875500703114551, createdTime=Thu Oct 05 12:22:00 CST 2017, time=2017-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1448759, encodeId=2b1b1448e5902, content=<a href='/topic/show?id=4a6f1104071' target=_blank style='color:#2F92EE;'>#LPS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11040, encryptionId=4a6f1104071, topicName=LPS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88135422756, createdName=shijzhiewnjhch, createdTime=Thu Oct 05 12:22:00 CST 2017, time=2017-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1529600, encodeId=cf1d152960056, content=<a href='/topic/show?id=e1c0814517e' target=_blank style='color:#2F92EE;'>#肝脏炎症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81451, encryptionId=e1c0814517e, topicName=肝脏炎症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=be0e11959960, createdName=zsyan, createdTime=Thu Oct 05 12:22:00 CST 2017, time=2017-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1536959, encodeId=fc1e15369590b, content=<a href='/topic/show?id=f1c512e304f' target=_blank style='color:#2F92EE;'>#NF-kB#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12730, encryptionId=f1c512e304f, topicName=NF-kB)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2ca12754731, createdName=jichang, createdTime=Thu Oct 05 12:22:00 CST 2017, time=2017-10-05, status=1, ipAttribution=)]
    2017-10-05 jichang